Zc(=o)oy, Wherein Z Is An Acyclic Radical Bonded To The C=o By A Carbon And Y Is An Organic Radical Bonded To The Oxygen By A Carbon Patents (Class 514/546)
  • Publication number: 20130142890
    Abstract: The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5? reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.
    Type: Application
    Filed: January 7, 2013
    Publication date: June 6, 2013
    Applicant: S.W. Patentverwertungs Limited
    Inventor: S.W. Patentverwertungs Limited
  • Publication number: 20130142872
    Abstract: The invention is a novel series of compounds represented by general formula, its analogs, tautomeric forms, stereoisomers, pharmaceutically acceptable salts and polymorphs wherein said compound described is a group of antisense molecules possessing immediate global cellular penetration due to their molecular structure and lipophilicity. The molecules are combinations of ethyl and methyl pyruvates. They induce riboswitch activity and reduce target RNA and nucleic acids such as HbA1c. They reduce inflammation and enhance energy production. These features improve therapeutic outcomes of diabetes, neuropathy and cellular aging.
    Type: Application
    Filed: August 9, 2012
    Publication date: June 6, 2013
    Inventors: John James Fitzgerald, JR., Ranya Ludwig Alexander, Anthony Joseph Meduri
  • Publication number: 20130136704
    Abstract: An object of the present invention is to provide a novel technology for preventing crystal precipitation of p-menthane-3,8-diol, and stable products utilizing this technology. Provided is a p-menthane-3,8-diol isomer mixture, wherein the mass ratio of cis isomers:trans isomers in terms of the relative configuration at Positions 3 and 4 is 55:45 to 45:55. Also provided are stable products and the like containing the p-menthane-3,8-diol isomer mixture.
    Type: Application
    Filed: November 27, 2012
    Publication date: May 30, 2013
    Applicant: TAKASAGO INTERNATIONAL CORPORATION
    Inventor: TAKASAGO INTERNATIONAL CORPORATION
  • Publication number: 20130131168
    Abstract: An application method of 1-monopropionine compound and its isoform 3-monopropionine being used as preserving agents in animal feeds, corns, grains, and other food materials. The monopropionine compounds are obtained by esterification reaction of propionic acid and glycerol. The product is a translucent viscous liquid composition comprising monopropionine compounds and other components, such as free acid, or certain salt forms of propionate. The generated composition can be further distilled in glycerol. The final product can take a liquid form or a powder form. 1-monopropionine compound and its isoform 3-monopropionine function as preserving agent at a low effective dosage of about 0.05 to 1% (by weight), and preferably 0.1 to 0.3% (by weight). A preferable application condition of this method is to preserve animal feeds and corns under a low (about 2% to 12%) moisture condition.
    Type: Application
    Filed: January 17, 2013
    Publication date: May 23, 2013
    Inventor: Paulo Roberto de Lima Portilho
  • Publication number: 20130131006
    Abstract: The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 23, 2013
    Applicant: Gachon University of Industry-Academic Cooperation Foundation
    Inventors: Bong Hee Lee, Kyung Hee Byun
  • Publication number: 20130131088
    Abstract: The disclosure pertains to methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a statin in combination with an effective amount of a dipyridamole and/or a compound that has dipyridamole activity.
    Type: Application
    Filed: January 13, 2011
    Publication date: May 23, 2013
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Linda Penn, Aaron Schimmer, Aleksandra Pandyra
  • Publication number: 20130131167
    Abstract: This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.
    Type: Application
    Filed: January 6, 2011
    Publication date: May 23, 2013
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
  • Patent number: 8445020
    Abstract: Disclosed are high-loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: May 21, 2013
    Assignee: Pharmalyte Solutions, LLC
    Inventors: Stephen F. Brandon, Feng Zhang, Stuart Schoenherr
  • Publication number: 20130123357
    Abstract: The present invention relates to a method of providing enhanced resveratrol activity comprising: administering a therapeutically effective amount of 4-acetoxy-resveratrol for the treatment of and preventing physiological and pathophysiological conditions mediated by (1) sirtuins, (2) estrogen and anti-estrogen hormone actions and (3) chemical interventions important for male and female health, aging, anti-aging and age-related disorders.
    Type: Application
    Filed: April 13, 2011
    Publication date: May 16, 2013
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: Edwin Douglas Lephart, Merritt B. Andrus
  • Publication number: 20130123358
    Abstract: Sodium butyrate was chronically administrated through diet supplementation at 5% w/w in a high fat diet. Supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6J mice on a high fat diet, and in mice fed on a regular diet of tributyrin. Fasting blood glucose, insulin, and insulin tolerance were all reserved in the butyrate-treated mice. The body fat content was maintained at 10% without a reduction in food intake. Adaptive thermogenesis and fatty acid oxidation were enhanced. An increase in mitochondria function and biogenesis was observed in the skeletal muscle and brown fat, and Type 1 muscle fiber was enriched in the skeletal muscle. In genetically obese mice, supplementation of butyrate led to an increase in insulin sensitivity and reduction in adiposity. Dietary supplementation of butyrate can prevent and treat diet-induced insulin resistance.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 16, 2013
    Inventors: Jianping Ye, Zhanguo Gao
  • Patent number: 8436013
    Abstract: The invention features compositions and methods that are useful for treating or preventing AAT deficiency and associated conditions. In addition, the invention provides methods for identifying compounds useful for treatment of AAT deficiency and associated conditions.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: May 7, 2013
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Chen Liu, David A. Ostrov
  • Patent number: 8436046
    Abstract: Biodegradable detergent compositions comprising 1,3-propanediol are provided, and the 1,3-propanediol in the composition is biologically derived. The compositions exhibit a lower anthropogenic CO2 emission profile. Also provided are biodegradable detergent compositions comprising an ester of 1,3-propanediol. In these compositions, the ester can have at least 3% biobased carbon.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: May 7, 2013
    Assignee: DuPont Tate & Lyle Bio Products Company, LLC
    Inventors: Gyorgyi Fenyvesi, Melissa Joerger, Robert Miller, Raja Hari Poladi, Ann Wehner
  • Publication number: 20130102663
    Abstract: An organoleptically acceptable composition containing a ketone body or a ketone body precursor including a hydroxybutyrate ester and a flavouring is provided and gives improved palatability and user adherence to the intended dose regime. The flavouring may be a bitter flavouring and the composition may further contain an adsorbent for the ketone such that on ingestion, the bitterness of the composition may be masked. The composition may be in the form of a solid, gel or liquid and provides increased blood ketone levels and may be used in therapy or in treating muscle impairment or fatigue.
    Type: Application
    Filed: February 22, 2011
    Publication date: April 25, 2013
    Applicant: TDELTAS LIMITED
    Inventor: Kieran Clarke
  • Publication number: 20130096192
    Abstract: Described herein are compositions (e.g., a pharmaceutical composition) and compounds of formula I, and their use in the treatment and/or prevention of diseases and disorders.
    Type: Application
    Filed: March 11, 2011
    Publication date: April 18, 2013
    Inventors: Joseph P. St. Laurent, Scott A. Goodrich, Gerald S. Jones, JR.
  • Publication number: 20130096092
    Abstract: Disclosed are inhibitors of retroviral growth of formula (I), that are useful in treatment of retroviral infections such as HIV. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, a method for inactivating a virus, a method for dissociating a metal ion from a zinc finger-containing protein, and a method for inhibiting the transmission of a virus.
    Type: Application
    Filed: June 10, 2011
    Publication date: April 18, 2013
    Applicants: Health and Human Services
    Inventors: Daniel Appella, Ettore Appella, John K. Inman, Lisa M. Miller Jenkins, Ryo Hayashi, Deyun Wang
  • Publication number: 20130089627
    Abstract: This invention provides a method for treating a cancer caused by cancer stem cells in a subject in need thereof, comprising administering to the subject an effective amount of Antrodia camphorata extracts. The invention also provides a method for treating a cancer caused by cancer stem cells in a subject in need thereof, comprising administering to the subject an effective amount of 4-acetyl-antroquinonol B.
    Type: Application
    Filed: October 11, 2012
    Publication date: April 11, 2013
    Applicant: NEW BELLUS ENTERPRISES CO., LTD.
    Inventor: NEW BELLUS ENTERPRISES CO., LTD.
  • Patent number: 8415391
    Abstract: The present invention pertains to a method of counteracting a malodor by introducing a malodor counteracting effective amount of a novel 3.2.1-bicyclo-octene or -octane compound represented by formula: wherein R is selected from the group consisting of hydrogen, acetate, carbonate monomethyl ester, and allyloxy; and wherein the broken line represents a single or double bond.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: April 9, 2013
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Benjamin Amorelli, Johan Gerwin Lodewijk Pluyter, Adam P. Closson
  • Publication number: 20130079405
    Abstract: Hydroxy acid compound of substituted phenyl ester, preparation method and medical use thereof are provided. The title compound is shown in formula (I), Y?C14 straight carbon chain. The compound can release 2,6-diisopropylphenol rapidly under the action of enzymes in vivo, which has sedative, hypnotic and/or anesthetic effect. By protecting the hydroxyl group of 2, 6-diisopropylphenol in compound of formula (I), the first-pass metabolic activity of 2, 6-diisopropylphenol is reduced, so that the synthetic compound can be used for sedation, hypnosis, and/or anesthesia.
    Type: Application
    Filed: October 13, 2010
    Publication date: March 28, 2013
    Applicant: West China Hospital Sichuan University
    Inventors: Wensheng Zhang, Jun Yang, Jin Liu
  • Publication number: 20130072509
    Abstract: A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to neurodegenerative diseases. A method of lowering lipid levels in an individual is also provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier, wherein lipid levels are decreased.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: ChromaDex Inc.
    Inventor: Jeremy Bartos
  • Publication number: 20130072559
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Krzysztof PALCZEWSKI, Matthew Batten
  • Publication number: 20130072561
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxyiates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: University of Washington
    Inventors: Tadao Maeda, David SAPERSTEIN, Krzysztof PALCZEWSKI
  • Publication number: 20130072557
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: University of Washington
    Inventors: Tadao Maeda, David Saperstein, Krzysztof Palczewski
  • Publication number: 20130072560
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Publication number: 20130072558
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: University of Washington
    Inventors: Tadao Maeda, David Saperstein, Krzysztof Palczewski
  • Publication number: 20130072556
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Krzysztof PALCZEWSKI, Matthew Batten
  • Publication number: 20130065909
    Abstract: The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.
    Type: Application
    Filed: November 9, 2012
    Publication date: March 14, 2013
    Applicant: CATABASIS PHARMACEUTICALS, INC.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Patent number: 8394854
    Abstract: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: March 12, 2013
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Aleardo Koverech
  • Publication number: 20130059382
    Abstract: In an embodiment of the disclosure, a biomedical material is provided. The biomedical material includes a biocompatible material having a surface and a carrier distributed over the surface of the biocompatible material, wherein both of the biocompatible material and the carrier have no charges, one of them has charges or both of them have charges with different electricity. The biomedical material is utilized for dentistry, orthopedics, wound healing or medical beauty and applied in the repair and regeneration of various soft and hard tissues.
    Type: Application
    Filed: September 6, 2012
    Publication date: March 7, 2013
    Inventors: Pei-Yi TSAI, Yi-Hung Wen, Zhi-Jie Huang, Pei-Shan Li, Hsin-Hsin Shen, Yi-Hung Lin, Chu-Hsun Lu
  • Publication number: 20130053441
    Abstract: A compound represented by the following formula (I?) wherein X1 is a methylene group, an ethylene group, a trimethylene group or a vinylene group, X2 is a divalent group represented by the following formula A or B, Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=0 to 8, R1 and R2 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that when X1 is a methylene group, then X2 is not a divalent group represented by the formula A, and when X1 is a vinylene group, then X2 is not a divalent group represented by the formula A. The compound is a stable capsinoid derivative, and is useful as an active ingredient of an external blood circulation enhancer or a cosmetic composition, a pharmaceutical composition, or a food composition.
    Type: Application
    Filed: June 26, 2012
    Publication date: February 28, 2013
    Applicant: AJINOMOTO CO., INC.
    Inventors: YUSUKE AMINO, YOSHINOBU TAKINO
  • Publication number: 20130046013
    Abstract: Fatty acid conjugates of salicylate derivatives and compositions thereof are disclosed. Further disclosed are methods for treating various diseases comprising the administration of an effective amount of at least one compound according to the present disclosure.
    Type: Application
    Filed: January 20, 2011
    Publication date: February 21, 2013
    Inventors: Ragnar Hovland, Tore Skæret, Jenny Rosman
  • Publication number: 20130040919
    Abstract: Active compounds of Formula I are described: wherein: R1 and R2 are each independently C1-C4 alkyl; or R1 and R2 together form a C2-C7 alkylene chain; and Z is a non-steroidal anti-inflammatory drug (NSAID); along with pharmaceutically acceptable salts and prodrug thereof, and methods of using the same.
    Type: Application
    Filed: August 20, 2012
    Publication date: February 14, 2013
    Inventor: S. Bruce King
  • Patent number: 8367721
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 5, 2013
    Assignee: Zafgen, Inc.
    Inventors: Thomas E. Hughes, James E. Vath
  • Publication number: 20130012557
    Abstract: Small molecule choline kinase inhibitors, pharmaceutical compositions thereof, and screening methods for identifying and evaluating choline kinase inhibitors are provided. Safe and effective methods for treating subjects suffering from a disorder or disease characterized by neoplastic cell proliferation employing the choline kinase inhibitors are also provided.
    Type: Application
    Filed: May 12, 2012
    Publication date: January 10, 2013
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Brian Clem, Sucheta Telang, John Trent, Jason Chesney, Pooran Chand, Gilles Tapolsky
  • Publication number: 20130011482
    Abstract: A medicament delivery system is disclosed. The system comprises a descending formulation for delivering the medicament and an ascending formulation to protect a patient being treated with the medicament from the side effects thereof.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Jose G. Rocca, Khalid Shah
  • Publication number: 20130005807
    Abstract: The objective of the present invention is to provide an antimicrobial composition that can be safely used with a broad range of foods and beverages, cosmetics, drugs, and other similar products while showing growth inhibition activity against a wide variety of microorganisms. The present invention relates to the antimicrobial composition comprising at least one cooling agent selected from the group consisting of menthyl 3-hydroxybutanoate, 2-methyl-3-(menthoxy)propane-1,2-diol, 2-(menthoxy)ethanol, 3-menthoxypropan-1-ol, 2-(2-menthoxyethoxy)ethanol, and menthyl glyoxylate.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 3, 2013
    Applicant: TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Kenya ISHIDA, Tomoko YAMAMOTO, Miho SUZUKI
  • Publication number: 20130005806
    Abstract: Embodiments of the invention include determining whether an individual has autism spectrum disorder or is at risk for developing autism spectrum disorder or at risk for regression of or into autism spectrum disorder. Specific embodiments include the determination of indicative levels of carnitine or other metabolites in carnitine biosynthesis and may include assaying for mutations in TMLHE, including in exon 2, for example. In some cases one can assay for mutations in TMLHE in the absence of biochemical analysis of carnitine biosynthesis metabolites. An individual with deficiency in TMLHE and/or carnitine levels may be administered carnitine, acetylcarnitine, butyrobetaine, or a combination thereof, for example.
    Type: Application
    Filed: June 18, 2012
    Publication date: January 3, 2013
    Inventors: Arthur L. Beaudet, Frederic M. Vaz
  • Patent number: 8338481
    Abstract: Disclosed are alkoxyalkyl S-prenylthiosalicylates and pharmaceutical compositions containing the same and a pharmaceutically acceptable carrier. Methods for treating a human afflicted with cancer, including solid tumors, or a hematological malignancy by administering to the human in need thereof an effective amount of an alkoxyalkyl S-prenylthiosalicylate are also disclosed.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: December 25, 2012
    Assignees: Ramot at Tel-Aviv University Ltd., Kadmon Corporation, LLC
    Inventors: Yoel Kloog, Liat Goldberg, Victor J. Bauer
  • Publication number: 20120323200
    Abstract: A cooling composition comprising a cooling agent together with a polyethylene glycol (PEG) or a mixture of different PEGs having high molecular weights and an absorbent article comprising the cooling composition. The cooling agent of the composition has a reduced tendency to vaporize and evaporate at room temperature.
    Type: Application
    Filed: June 14, 2012
    Publication date: December 20, 2012
    Applicant: The Procter & Gamble Company
    Inventor: Alessandro Gagliardini
  • Publication number: 20120316235
    Abstract: Provided is a mating disruption method capable of bringing a stable and effective mating disruption result. Specifically provided is a mating disruption method comprising a step of starting to apply a mating disruptant after mating and oviposition of imagoes of the first generation of an insect pest are substantially over and before imagoes of the second generation of the insect pest emerge, the mating disruptant targeting at least one kind of insect pest which contains one or more kinds of acetates as a natural sex pheromone.
    Type: Application
    Filed: June 7, 2012
    Publication date: December 13, 2012
    Applicant: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Kinya Ogawa, Tatsuya Hojo
  • Patent number: 8318804
    Abstract: Disclosed is a method of synthesizing new optically pure heterocyclic compounds using Pd(0) catalyzed intramolecular cyclizations. Analogs of cyclopentanes, like isoxazoline-2-oxide and furan, with similar framework to the cyclopentanes act as anti-HIV and anticancer agents which opens a whole new field for application of these compounds. Starting from a meso-diol, optically pure compounds were prepared without utilizing chiral ligands at any stage of the synthesis. The stereochemical outcome of the product (>99% ee) was influenced by desymmetrization catalyzed by Pseudomonas cepacia lipase and the stereo selective nature of the palladium catalyzed transformations.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: November 27, 2012
    Assignee: University of South Florida
    Inventors: Kirpal S. Bisht, Alberto Van Olphen, Pasha M. Khan, Cynthia Bucher
  • Publication number: 20120295972
    Abstract: Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.
    Type: Application
    Filed: February 13, 2012
    Publication date: November 22, 2012
    Inventors: David F. Woodward, Jenny W. Wang, Neil J. Poloso, Todd Gac, Robert M. Burk, Michael E. Garst
  • Publication number: 20120294958
    Abstract: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.
    Type: Application
    Filed: July 30, 2012
    Publication date: November 22, 2012
    Applicant: BASF CORPORATION
    Inventor: Steven R. Sims
  • Patent number: 8314144
    Abstract: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: November 20, 2012
    Assignee: Defiante Farmaceutica, S.A.
    Inventors: Gianfranco Peluso, Menotti Calvani
  • Patent number: 8309610
    Abstract: This invention relates to solid crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutical compositions comprising 1.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: November 13, 2012
    Assignee: Gruenenthal GmbH
    Inventors: Michael Gruss, Helmut Buschmann, Andreas Fischer, Wolfgang Hell, Dagmar Lischke
  • Patent number: 8309062
    Abstract: The present invention provides a cooling component or sensate component which does not have undesirable stimulus feeling, bitterness and the like and is excellent in the persistence of refresh-feeling and cool-feeling, a sensate composition which comprises the same, and various products that comprise said sensate composition.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: November 13, 2012
    Assignee: Takasago International Corporation
    Inventors: Kazuma Hojo, Takashi Aida, Kenya Ishida
  • Patent number: 8309588
    Abstract: This invention relates to synergistic combinations of selected microbicides in combination with a second microbicide or formulation ingredient or raw material. The combinations have greater efficacy than would be expected from combinations of the individual components. The combinations include mixtures of (a) 5-Chloro-2-methyl-4-isothiazolin-3-one+2-Methyl-4-isothiazolin-3-one, (b) Methyl-4-isothiazolin-3-one, or (c) 1,2-Benzisothiazolin-3-one with one or more of a variety of other compounds.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: November 13, 2012
    Assignee: Rohm and Haas Company
    Inventors: Megan Ann Diehl, Dolores A. Shaw
  • Publication number: 20120282202
    Abstract: An aqueous composition for topical application includes at least 60% w/w of a C1-C4 alkyl lactate ester, at least 1% w/w water, having a pH in the range from 1-6, and an effective amount of at least one physically acceptable antioxidant. A method is provided for the preparation, and the use of the composition for the treatment of fungus infections of nails and/or skin, in particular onychomycosis and tinea pedis, and an applicator device for performing such treatment.
    Type: Application
    Filed: October 27, 2010
    Publication date: November 8, 2012
    Inventor: Miriam Clapposen
  • Publication number: 20120277315
    Abstract: A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
    Type: Application
    Filed: June 12, 2012
    Publication date: November 1, 2012
    Inventors: Marshall D. Crew, William J. Curatolo, Dwayne T. Friesen, Michael Jon Gumkowski, Dougles A. Lorenz, James A. S. Nightingale, Roger B. Ruggeri, Ravi M. Shanker
  • Publication number: 20120277308
    Abstract: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.
    Type: Application
    Filed: July 15, 2011
    Publication date: November 1, 2012
    Applicant: PACIFIC ARROW LIMITED
    Inventors: Pui-Kwong Chan, May Sung Mak
  • Patent number: 8299120
    Abstract: The invention relates to a method of ameliorating multiple sclerosis and/or the symptoms of multiple sclerosis in a mammal, which comprises administering or having self administered to the mammal an effective amount of (a) cetyl myristate or (b) cetyl myristate and cetyl palmitate. In preferred embodiments the mode of administration is oral and both cetyl myristate and cetyl palmitate are administered.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: October 30, 2012
    Assignee: Lypanosis Pte Limited
    Inventors: Dianne Cadwallader, Timothy Meakin